Leuprolide


Synthetic GnRH agonist (nonapeptide)

A synthetic GnRH agonist; the most prescribed GnRH analog worldwide; approved for prostate cancer, endometriosis, fibroids, and precocious puberty.

Abstract

Leuprolide (5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide; CAS 53714-56-0; molecular formula C59H84N16O12; molecular weight 1209.41) is a synthetic GnRH agonist nonapeptide developed at Abbott and approved by the FDA in 1985 under the trade name Lupron. Mechanism is identical to triptorelin: chronic exposure desensitizes pituitary GnRH receptors and suppresses LH/FSH after an initial 1-to-2-week flare. Plasma half-life is approximately 3 hours for the parent peptide; depot formulations release over 1, 3, 4, or 6 months. Leuprolide is the most prescribed GnRH analog globally and is the workhorse of clinical GnRH suppression. Approved indications: prostate cancer, endometriosis, uterine leiomyomata (fibroids), central precocious puberty, IVF protocols, and (recently) delayed puberty in transgender adolescents in some markets. Used as the canonical GnRH agonist in academic endocrine pharmacology and as a pharmacological tool for HPG axis manipulation.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph